10-Q: Pelthos Therapeutics Reports Q3 2025 Results, ZELSUVMI Launch

Pelthos Therapeutics Inc. reported its Q3 2025 financial results, marking its first product revenues following the commercial launch of ZELSUVMI, alongside significant merger and financing activities, but also disclosed substantial net losses and material weaknesses in internal controls.

Summary

• Pelthos Therapeutics Inc. was effectively formed on July 1, 2025, through a merger between Channel Therapeutics Corporation and LNHC, Inc.
• The company commercially launched ZELSUVMI (berdazimer) topical gel, 10.3% for molluscum contagiosum in July 2025, following its FDA approval in January 2024.
• Net product revenues for the three and nine months ended September 30, 2025, were $7.112 million, representing the company's first product sales.
• Total revenue for the three and nine months ended September 30, 2025, was $7.406 million, including $0.294 million from license and collaboration agreements.
• The company reported a net loss of $16.238 million for Q3 2025 and $21.655 million for the nine months ended September 30, 2025.
• Selling, general, and administrative (SG&A) expenses significantly increased to $19.628 million for Q3 2025 and $23.984 million for the nine months, primarily due to ZELSUVMI's commercial launch.
• Research and development (R&D) expenses decreased to $0.145 million for Q3 2025 and $0.854 million for the nine months.
• Cash and cash equivalents increased to $14.203 million as of September 30, 2025, from $0.513 million at December 31, 2024, largely due to a $27.384 million net proceeds from a PIPE financing.
• Working capital improved to $24.993 million as of September 30, 2025, from a deficit of $2.714 million at December 31, 2024.
• Management expressed substantial doubt about the company's ability to continue as a going concern for at least the next twelve months, citing expected ongoing losses and the need for additional capital.
• Material weaknesses in internal controls over financial reporting were identified, including a lack of segregation of duties, insufficient levels of review, and inadequate internal IT infrastructure.
• A default judgment was entered on October 7, 2025, in favor of the company against its former CEO, Mr. Christian Kopfli, and Chromocell Holdings for $17.951 million, plus an additional $0.348 million against Mr. Kopfli.
• The company settled a demand letter from former CMO Dr. Eric Lang without paying liquidated damages.
• Post-quarter, on November 6, 2025, the company secured an $18.0 million convertible note financing, acquired Xepi (ozenoxacin) cream assets for up to $10.0 million, and entered into a license agreement for Xepi with Ferrer Internacional, S.A.

Sentiment

Score: 4

Explanation: While the commercial launch of ZELSUVMI and recent financing activities provide some positive momentum, the substantial net losses, explicit going concern doubt, and identified material weaknesses in internal controls present significant challenges and risks, leading to a cautious sentiment.

Positives

• Successful commercial launch of ZELSUVMI in July 2025, generating $7.112 million in net product revenues for the three and nine months ended September 30, 2025.
• ZELSUVMI is the first FDA-approved at-home prescription medication for molluscum contagiosum, offering a differentiated treatment option.
• Significant increase in cash and cash equivalents to $14.203 million and positive working capital of $24.993 million as of September 30, 2025, largely due to the PIPE financing.
• Successful completion of a Private Investment in Public Equity (PIPE) financing, raising approximately $50.1 million in gross proceeds.
• Favorable legal outcome with a default judgment of $17.951 million plus $0.348 million awarded to the company in the Kopfli Matter.
• Acquisition of Xepi (ozenoxacin) cream assets and a related license agreement post-quarter, diversifying the product portfolio.
• The company possesses its own API manufacturing facility with excess capacity, providing critical control over its supply chain and potential for future growth.

Negatives

• Reported a substantial net loss of $16.238 million for the three months and $21.655 million for the nine months ended September 30, 2025.
• Significant increase in operating expenses, particularly Selling, General and Administrative (SG&A) expenses, due to commercialization efforts.
• Substantial doubt about the company's ability to continue as a going concern for the next twelve months, necessitating additional capital raises.
• Identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties, insufficient review levels, and inadequate IT infrastructure.
• High interest expense of $1.346 million for Q3 2025 and $1.698 million for the nine months, primarily from royalty obligations and debt.

Risks

• Ability to obtain additional capital in the future and generate sufficient cash flows from operations to continue as a going concern.
• Reliance on a few significant wholesale customers, with three customers accounting for over 94% of total gross accounts receivable, posing concentration risk.
• Potential for dilution of existing stockholders if additional funds are raised by issuing securities.
• Challenges in effectively implementing and maintaining sales, marketing, and distribution capabilities for ZELSUVMI.
• Need for broad physician and patient adoption of ZELSUVMI for commercial success.
• Delays or disruptions in the supply chain and manufacturing of products could adversely affect sales and marketing efforts.
• Unexpected results in raw material, API, or drug product analysis, or issues with quality systems, could impact commercialization.
• Competition from major pharmaceutical companies, other topical products, natural remedies, and medical procedures for molluscum contagiosum.
• Potential impact of government initiatives like the 'Most-Favored-Nation Prescription Drug Pricing' executive order on international pricing and opportunities for ZELSUVMI.
• Uncertainty regarding the timing and budget for commencing toxicology and CMC work and human POC trials for the NaV1.7 pain programs.

Future Outlook

The company expects to continue incurring losses for the foreseeable future due to ongoing investments in ZELSUVMI commercialization, operational system enhancements, and potential clinical trials for its pain programs. Additional funds will be required to support these activities, and there is no assurance that such funds will be raised on acceptable terms. The company aims to expand ZELSUVMI's market presence and explore international opportunities, while also periodically reviewing the timing and budget for its NaV1.7 pain programs.

Management Comments

• Management believes there is substantial doubt about the company's ability to continue to operate as a going concern and fund its operations through at least the next twelve months.
• Management believes in the viability of the company's strategy to generate sufficient revenue, control costs, and raise additional funds, when necessary, but there can be no assurances to that effect.
• The company believes that ZELSUVMI is likely to complement or represent a differing treatment regimen of current procedural treatments administered in medical settings such as cryosurgery, cantharidin application and curettage.
• The company believes that pediatricians will be key to expanding the market, increasing peak sales, and sales and marketing efficiency for ZELSUVMI.
• The company believes the NITRICIL technology platform has many other potential product candidates that could be further developed.

Industry Context

Pelthos Therapeutics operates in the highly competitive biopharmaceutical industry, characterized by rapid technological advancements and a strong emphasis on proprietary products. The launch of ZELSUVMI positions the company as a pioneer in the molluscum contagiosum treatment market, being the first FDA-approved at-home prescription topical therapy. This offers a significant advantage over existing procedural treatments and off-label remedies. The company's strategic focus on its NITRICIL platform and NaV1.7 pain programs aligns with broader industry trends towards innovative drug delivery and targeted pain management, an area with high unmet medical needs. However, the industry also faces challenges such as intense competition, regulatory hurdles, and pricing pressures, as highlighted by the 'Most-Favored-Nation Prescription Drug Pricing' executive order, which could impact future international expansion and profitability.

Comparison to Industry Standards

• ZELSUVMI is the first and only FDA-approved prescription pharmaceutical therapy for the treatment of molluscum contagiosum that can be administered by patients or caregivers outside of a medical setting, differentiating it from competitors like cryosurgery, cantharidin application, and curettage.
• The company's proprietary NITRICIL technology platform, validated by ZELSUVMI's FDA approval, demonstrates a unique approach to nitric oxide delivery, potentially offering a competitive edge in developing future product candidates compared to traditional drug development methods.
• The NaV1.7 pain programs target a genetically validated pain receptor, aiming to develop a novel class of peripheral nervous system blockers, which could offer a safer alternative to existing pain therapies (e.g., opioids) by avoiding CNS-mediated side effects like addiction, a significant concern in the pain management industry.
• The acquisition of Xepi (ozenoxacin) cream, an antibacterial for impetigo, diversifies the company's dermatology portfolio, potentially leveraging existing sales and distribution channels for ZELSUVMI, similar to how larger pharmaceutical companies build therapeutic franchises.

Management Changes

Corporate Governance

Legal Proceedings

• In the Kopfli Matter, a default judgment was entered on October 7, 2025, in favor of Chromocell (now Pelthos) against Mr. Christian Kopfli and Chromocell Holdings, jointly and severally, for $17,950,810, plus additional damages against Mr. Kopfli for $348,461. The company had previously accrued $363,091 in compensation expenses related to Mr. Kopfli, which was removed as of June 30, 2025.
• The company received a demand letter from Dr. Eric Lang, former Chief Medical Officer, asserting potential liability of up to $1,008,095 for alleged breach of employment contract and violations of wage and hour laws. The company settled the matter without payment of any liquidated damages and believes it is fully resolved.

Related Party Transactions

• Ligand Pharmaceuticals, Inc. (Ligand) is a significant related party, having formed LNHC, Inc., and being a major investor in the PIPE Financing. Ligand received 31,278 shares of Series A Preferred Stock as consideration for the LNHC merger.
• Ligand is a party to the ZELSUVMI License Agreement, entitling it to a 13% royalty on worldwide ZELSUVMI sales (excluding Japan) and milestone payments, and also a party to the Ligand Master Services Agreement and Transition Services Agreement.
• Madison Royalty LLC, a Colorado limited liability company, is a purchaser in the Channel Products Royalty Agreement. This entity was formed on behalf of certain legacy Channel directors and management, with the company's Chief Financial Officer, Mr. Francis Knuettel II, as the sole and managing member as of September 30, 2025.
• Camden Capital LLC, a company controlled by Mr. Francis Knuettel II (CFO), had a promissory note for $132,000 converted from certain payables on May 10, 2024. This note has been fully satisfied as of September 30, 2025, with $32,000 repaid in principal and $8,000 in accrued interest, and $100,000 converted into common stock as part of the Merger and PIPE Financing.
• Post-quarter, Ligand is also an investor in the $18.0 million Convertible Note Financing and serves as the Collateral Agent under the Pledge Agreement for the Convertible Notes.

Stakeholder Impact

• Shareholders: Experienced significant dilution from the PIPE financing and conversion of preferred stock to common stock. Face substantial doubt about the company's going concern ability and potential for further dilution from future capital raises. Benefit from the commercial launch of ZELSUVMI and the favorable legal judgment in the Kopfli matter.
• Employees: The company is adding operational, financial, and management personnel to support growth. However, material weaknesses in internal controls could impact employee processes and morale.
• Customers (Wholesalers/Distributors): ZELSUVMI is distributed through three wholesalers and one specialty distributor, with high concentration risk (three customers account for over 94% of receivables).
• Patients: Benefit from the availability of ZELSUVMI as the first FDA-approved at-home prescription treatment for molluscum contagiosum. Future pain programs (NaV1.7) and the Xepi acquisition could offer additional therapeutic options.
• Creditors: The company's going concern doubt and need for additional financing pose risks. The $18.0 million convertible notes are secured by future royalty payments, providing some collateral.
• Regulatory Authorities: The company is subject to SEC filing requirements and has identified material weaknesses in internal controls, which will require remediation.

Next Steps

• Continue to invest in commercialization activities for ZELSUVMI, including sales, marketing, and distribution efforts.
• Add operational, financial, and management information systems and personnel to support company operations.
• Raise additional funds to support ongoing operations and future growth, including potential clinical trials for existing pain programs.
• Address and remediate identified material weaknesses in internal controls over financial reporting.
• Negotiate a development and funding agreement to obtain rights to develop and commercialize the SB207 product program within one year of the ZELSUVMI License effective date.
• Prepare and file a resale registration statement with the SEC for shares of common stock issuable upon conversion of the Convertible Notes by the 60th calendar day following November 6, 2025.

Key Dates

Recommendation

Pelthos Therapeutics Inc. presents a mixed financial picture. The successful commercial launch of ZELSUVMI and the recent PIPE financing, along with the post-quarter acquisition of Xepi, demonstrate strategic execution and potential for future revenue growth in the dermatology and pain management sectors. The favorable legal judgment also provides a significant financial boost. However, the substantial net losses, explicit 'going concern' warning, and identified material weaknesses in internal controls introduce considerable risk and uncertainty. While the company has a promising commercial product and pipeline assets, its immediate financial stability and operational integrity are under scrutiny. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the long-term potential driven by ZELSUVMI's market position and pipeline diversification, but also recognizing the significant near-term financial and operational challenges that warrant close monitoring before a more definitive stance can be taken.

Keywords

Pelthos Therapeutics, PTHS, ZELSUVMI, Molluscum Contagiosum, Biopharmaceutical, SEC Filing, 10-Q, Quarterly Report, Drug Launch, PIPE Financing, Going Concern, Internal Controls, NaV1.7, Pain Programs, Xepi, Acquisition, Royalty Agreements, FDA Approved, Nitricil Technology